Integrated screening of quality markers from Paris polyphylla var. yunnanensis using UHPLC-Q/TOF-HRMS, spectrum-effect relationship analysis, network pharmacology, and quantitative analysis
Pengjuan Li, Hongbo Xu, Shuming Li, Jingyu Weng, Yuangui Yang
{"title":"Integrated screening of quality markers from Paris polyphylla var. yunnanensis using UHPLC-Q/TOF-HRMS, spectrum-effect relationship analysis, network pharmacology, and quantitative analysis","authors":"Pengjuan Li, Hongbo Xu, Shuming Li, Jingyu Weng, Yuangui Yang","doi":"10.1016/j.jpba.2025.117140","DOIUrl":null,"url":null,"abstract":"<div><div>This study aims to comprehensively screen quality markers using an integrated multi-strategy approach combining plant metabolomics, spectrum-effect relationship analysis, network pharmacology, and quantitative analysis, thereby providing a basis for quality control of <em>Paris polyphylla</em> var. <em>yunnanensis</em> and its closely related species. Firstly, 14 differential metabolites were screened from the roots, stems, and leaves of <em>Paris polyphylla</em> var. <em>yunnanensis</em> using UHPLC-Q/TOF-HRMS combined with principal component analysis and partial least squares-discriminant analysis. Secondly, fingerprint profiles of the roots, stems, and leaves of <em>Paris polyphylla</em> var. <em>yunnanensis</em> were established by UHPLC-Q/TOF-HRMS, identifying 22, 26, and 15 common peaks, respectively. By integrating grey relational analysis, bivariate correlation analysis, and partial least squares regression, five potential quality markers (<em>β</em>-Ecdysone, polyphyllin VII, II, I, and V) were preliminarily screened from <em>Paris polyphylla</em> var. <em>yunnanensis</em>. Subsequently, through network pharmacology and molecular docking, four quality markers (polyphyllin VII, II, I, and V) were ultimately identified. Finally, HPLC-DAD quantitative analysis revealed differential capabilities in accumulating and storing these quality markers among <em>Paris polyphylla</em> var. <em>yunnanensis</em> and its closely related species. In summary, this study holds significant implications for elucidating the pharmacodynamic material basis of <em>Paris polyphylla</em> var. <em>yunnanensis</em>, screening core efficacy-related quality markers through spectrum-effect relationships, and ensuring quality control and rational utilization of Paridis Rhizoma.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"268 ","pages":"Article 117140"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0731708525004819","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
This study aims to comprehensively screen quality markers using an integrated multi-strategy approach combining plant metabolomics, spectrum-effect relationship analysis, network pharmacology, and quantitative analysis, thereby providing a basis for quality control of Paris polyphylla var. yunnanensis and its closely related species. Firstly, 14 differential metabolites were screened from the roots, stems, and leaves of Paris polyphylla var. yunnanensis using UHPLC-Q/TOF-HRMS combined with principal component analysis and partial least squares-discriminant analysis. Secondly, fingerprint profiles of the roots, stems, and leaves of Paris polyphylla var. yunnanensis were established by UHPLC-Q/TOF-HRMS, identifying 22, 26, and 15 common peaks, respectively. By integrating grey relational analysis, bivariate correlation analysis, and partial least squares regression, five potential quality markers (β-Ecdysone, polyphyllin VII, II, I, and V) were preliminarily screened from Paris polyphylla var. yunnanensis. Subsequently, through network pharmacology and molecular docking, four quality markers (polyphyllin VII, II, I, and V) were ultimately identified. Finally, HPLC-DAD quantitative analysis revealed differential capabilities in accumulating and storing these quality markers among Paris polyphylla var. yunnanensis and its closely related species. In summary, this study holds significant implications for elucidating the pharmacodynamic material basis of Paris polyphylla var. yunnanensis, screening core efficacy-related quality markers through spectrum-effect relationships, and ensuring quality control and rational utilization of Paridis Rhizoma.
期刊介绍:
This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.
Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.